Production of cultured human mast cells and basophils for high throughput small molecule drug discovery

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7070996
APP PUB NO 20030077824A1
SERIAL NO

10053355

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
RIGEL PHARMACEUTICALS, INC.SOUTH SAN FRANCISCO, CA346

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Rossi, Alexander B San Francisco, CA 33 1656

Cited Art Landscape

Patent Info (Count) # Cites Year
 
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (1)
6225044 Method for gene transfer into cells activated from a quiescent state 4 1999
 
CELLDEX THERAPEUTICS, INC. (3)
5554512 Ligands for flt3 receptors 31 1994
5843423 Methods of stimulating hematopoietic cells with flt3-ligand 55 1997
6190655 Methods of using Flt-3 ligand for exogenous gene transfer 15 1998
 
NORTHWESTERN UNIVERSITY (1)
6261841 Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells 6 2000
 
DANA-FARBER CANCER INSTITUTE, INC. (1)
4559310 Assay methods and systems utilizing mast cell clones 14 1983
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RIGEL PHARMACEUTICALS, INC. (18)
7557210 2,4-pyrimidinediamine compounds and their uses 77 2003
* 2004/0029,902 2,4-Pyrimidinediamine compounds and their uses 108 2003
8178671 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds 13 2004
* 2005/0234,049 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds 118 2004
7521560 2-substituted quinoline compounds and their uses 0 2005
7435814 2,4-Pyrimidinediamine compounds and their uses 47 2005
7582648 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 65 2006
* 2008/0312,438 METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS 49 2006
7452879 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 68 2006
7659280 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 11 2007
* 2007/0197,782 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES 66 2007
7655797 Intermediates for making 2,4-pyrimidinediamine compounds 41 2008
* 2009/0082,567 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES 6 2008
7803939 2,4-pyrimidinediamine compounds and their uses 39 2008
* 2009/0171,085 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES 3 2008
8334296 2,4-pyrimidinediamine compounds and their uses 16 2008
* 2009/0156,622 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES 40 2008
8314093 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 0 2009
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00